Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Besremi and Vemlidy with or without UDCA in HBV/HDV co-infection
NCT05467553Phase 2Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Feb 2023
- Primary completion
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ropeginterferon alfa-2b in hepatitis B (HBV), hepatitis D (HDV), sponsored by National Taiwan University Hospital. Status: unknown.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
hepatitis B (HBV)hepatitis D (HDV)
Beyond the preview
Go deeper on NCT05467553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05467553.